While the effects of liraglutide+PYY3-36 on NAFLD are comparable to the effects of RYGB, liraglutide+PYY3-36 has no significant effect on metabolic markers, contrary to RYGB. The gene discussed is PYY3; the disease is metabolic dysfunction-associated steatotic liver disease.